I was wondering when they would get around to the Apo issue given that for quite some time Apo has been less relevant as a quantifying yardstick for RVX compounds and would be very limiting as to overall participation by that measure. As a holder of both RVX as well as Zenith I am rather ambivalent wrt the royalty preferred share vote but will be interesting to see how the vote goes. I imagine it will pass handily but like some here Hepalink is currently not a holder of Zenith. I wonder if they will be stepping up to invest in Zenith?